Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HK2 | P52789 | 6/20 | 0.50 |
| ▸ | HK1 | P19367 | 5/20 | 0.49 |
| ▸ | PYGB | P11216 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30019948 | 1.00 | LMNA (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL1673868 | 1.00 | LMNA (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL3966078 | 1.00 | LMNA (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL13742863 | 0.84 | KDM4E (0.42) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL17210624 | 0.84 | KDM4E (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL15590477 | 0.84 | KDM4E (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL8930010 | 0.84 | KDM4E (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL18407097 | 0.84 | LMNA (0.57) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL21753475 | 0.84 | KDM4E (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 | |
| SCHEMBL12371561 | 0.84 | KDM4E (0.54) | LMNAKDM4ECYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086767-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | INSTITUT PASTEUR | 2011-04-14 | — | — | US | disclosed |
| EP-2100965-A1 | Mutants of glycoside hydrolases and uses thereof for synthesizing complex oligosaccharides and disaccharide intermediates | Institut Pasteur (FR) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086767-A1 | MUTANTS OF GLYCOSIDE HYDROLASES AND USES THEREOF FOR SYNTHESIZING COMPLEX OLIGOSACCHARIDES AND DISACCHARIDE INTERMEDIATES | ENGASE, GALE, MGAM | LMNA 3194/4885KDM4E 3950/4885CYP2D6 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.